ClinicalTrials.Veeva

Menu
A

Associated Medical Professionals of NY, PLLC | Syracuse, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Enzalutamide
Darolutamide
Androgen
Pembrolizumab
Relugolix
Bicalutamide
Fesoterodine
MK-3475-991
valacyclovir
Apalutamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 33 total trials

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200
Locations recently updated

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Cancer
Drug: Gemcitabine
Drug: MMC

The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in pa...

Active, not recruiting
Metastatic Hormone-sensitive Prostate Cancer
Other: ADT
Drug: Darolutamide (BAY1841788, Nubeqa)
Locations recently updated

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Enrolling
High-risk Non-muscle Invasive Bladder Cancer
Biological: Pembrolizumab
Biological: BCG

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate...

Enrolling
Prostate Cancer
Radiation: Radiation Therapy
Drug: Darolutamide

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerat...

Active, not recruiting
Urinary Urgency Incontinence
Device: Neuspera Implantable Sacral Nerve Stimulation System

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with interm...

Active, not recruiting
Prostate Cancer
Biological: Placebo + valacyclovir
Biological: Aglatimagene besadenovec + valacyclovir

The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostat...

Active, not recruiting
Prostate Cancer
Biological: placebo
Drug: valacyclovir

This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Biological: Pembrolizumab

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Bayer logo
D
C
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Sumitomo Pharma logo
A
B
Boston Scientific logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems